Trial Profile
Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 08 Mar 2024 Last checked against ClinicalTrials.gov record.
- 14 Feb 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2025.
- 14 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2025.